1. Bronchoconstriction is due to an activation of parasympathetic nervous system. Postganglionic parasympathetic fibers will release acetylcholine (ACh) next to the Reissessen muscle, a smooth muscle layer surrounding the bronchi. These smooth muscle cells have M3 type muscarinic receptors on their membrane. The activation of these receptors by ACh will activate an intracellular Gq protein, that in turn will activate the PLC pathway, that will end in an increase of intracellular calcium concentrations and therefore contraction of the smooth muscle cell. The muscle contraction will cause the diameter of the bronchus to decrease, therefore increasing its resistance.
2. Bronchoconstriction (definition) is defined as the narrowing of the airways in the lungs (bronchi and bronchioles). Air flow in air passages can get restricted due to 3 factors: - a spasmodic state of the smooth muscles in bronchi and bronchioles - an inflammation of the airways - excessive production of mucus due to an allergic reaction or irritation caused by mechanical friction of air (due to shear stress), overcooling or drying of airways. Bronchoconstriction is common in people with respiratory problems, such as asthma, COPD, and cystic fibrosis.
With emphysema the shortness of breath due to effective bronchoconstriction from excessive very thick mucous blockage (it is so thick that great difficulty is encountered in expelling it resulting in near exhaustion at times) can bring on panic attacks unless the individual expects this and has effectively learned pursed lip breathing to more quickly transfer oxygen to the blood via the damaged alveoli resulting from the disease. The most common cause of emphysema is smoking and smoking cessation is mandatory if this incurable disease is to be treated. Prevention of bronchoconstriction by this pathway is vital for emphysema sufferers and there are several anticholinergic medications that can greatly improve the quality of life for these individuals. In combination with mucous thinning agents such as Guaifenesin significant improvement in breathing can be accomplished.
More generally termed exercise-induced asthma, the preferred and more accurate term exercise-induced bronchoconstriction better reflects underlying pathophysiology. It is also preferred due to the former term giving the false impression that asthma is caused by exercise.
In a patient with EIB, exercise initially follows the normal patterns of bronchodilation. However, by three minutes, the constriction sets in, which peaks at around 10–15 minutes, and usually resolves itself by an hour. During an episode of this type of bronchorestriction, the levels of inflammatory mediators, particularly leukotrienes, histamine, and interleukin, increase. TH2-type lymphocytes are activated, with an increase in T cells expressing CD25 (IL-2R), and B cells expressing CD 23, causing increased production of IgE. After exercise, the conditions will fade within one to three minutes. In most sufferers of EIB, this is followed by a refractory period, of generally less than four hours, during which if exercise is repeated, the bronchorestriction is less emphasised. This is probably caused by the release of prostaglandins.
The underlying cause of this type of bronchoconstriction appear to be the large volume of cool, dry air inhaled during strenuous exercise. The condition appears to improve when the air inhaled is more fully humidified and closer to body temperature.
This specific condition, in the general population, can vary between 7 and 20 percent. This increases to around 80 percent in those with symptomatic asthma. In many cases, however, the constriction, even during or after strenuous exercise, is not clinically significant except in cases of severe to moderate emphysema.
In May 2013, the American Thoracic Society issued the first treatment guidelines for EIB (http://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0437ST).
While a different cause, this has very similar symptoms, namely the immunological reaction involving release of inflammatory mediators.
Inhalation of allergens in sensitized subjects develops into bronchorestriction within 10 minutes, reaches a maximum within 30 minutes, and usually resolves itself within one to three hours. In some subjects, the constriction does not return to normal, and recurs after three to four hours, which may last up to a day or more. The first is named the early asthmatic response, and the latter the late asthmatic response.
Bronchioconstriction can occur as a result of anaphylaxis, even when the allergen is not inhaled.
Medical management of transient bronchoconstriction or chronic bronchitis depends on the severity and etiology of the underlying disease and can be treated with combinations of the following medications:
- B-receptor agonists: Medications that stimulate the β2 receptor subtype on pulmonary smooth muscle will result in smooth muscle relaxation, bronchodilation, and increased airflow into the lungs during inhalation. These medications include short-acting beta agonists (SABAs) such as albuterol which typically last 4–6 hours, and long-acting beta agonists (LABAs) such as salmeterol which lasts 12 hours. For example, during an acute asthma exacerbation where airway smooth muscle is constricted, inhalation of SABAs provide rapid relief of symptoms—within 5–15 minutes—and are typically called “rescue inhalers”. Due to their fast onset of action, they have been selected as first-line therapy for quick relief in persistent and intermittent asthma and bronchospasm. Patients may experience dizziness, heart palpitations, hyperglycemia, diarrhea and muscle cramps when taking these medications. Importantly, medications that antagonize the β2 receptor (β-blockers) may significantly increase the risk of asthma exacerbations, and are generally avoided in asthmatic patients.
- Corticosteroids: Inhaled corticosteroids (i.e. fluticasone, budesonide) are typically used when bronchoconstrictive disease has advanced to a persistent inflammatory state, more specifically in persistent or severe asthma and chronic obstructive pulmonary disease (COPD). These medications decrease immune system activity which in turn will decrease swelling of the airways, decrease airway resistance, and increase delivery of air to the alveoli during respiration. Unlike the SABAs, these medications do not provide relief of acute symptoms or asthmatic attacks, and their benefits are typically only seen after 3–4 weeks of therapy. Due to this delayed therapeutic response, it is absolutely essential that patients who are prescribed corticosteroids for respiratory disease are adherent to their medication regimen. In the ISOLDE trial, fluticasone therapy decreased the frequency of COPD exacerbations and the rate of health decline in patients with moderate-to-severe COPD; however, had little effect in decreasing the rate of FEV1 decline. Patients should be counseled to wash their mouth following use of inhaled corticosteroids to decrease the risk of developing oral thrush, a common side effect of these medications.
- Muscarinic antagonists (anti-cholinergics): Blocking the muscarinic acetylcholine receptors in pulmonary smooth muscle tissue results in a decrease in smooth muscle tone and bronchodilation. These medications include short-acting muscarinic antagonists (SAMAs) such as ipratropium, and long-acting muscarinic antagonists (LAMA) such as tiotropium. Onset of action for SAMAs is typically between 30–60 minutes, making these drugs less efficacious in treating acute asthma attacks and bronchospasm. Most common side effects for these drugs may include dry mouth, headache, urinary tract infection, and bronchitis.
- Other: Other prescription and over-the-counter medications, such as theophylline, cromolyn, and montelukast are indicated for specific diseases and may only provide bronchoconstriction relief to these studied populations.
- Timothy D. Mickleborough, PhD, FACSM (April 2010). "Salt Intake, Asthma, and Exercise-Induced Bronchoconstriction: A Review". The Physician and SportsMedicine. 38 (1): 118–131. doi:10.3810/psm.2010.04.1769. PMID 20424409.
- Rau, JL. "Inhaled adrenergic bronchodilators: historical development and clinical application". Respir Care 45 (7): 854–63. PMID 10926383.
- National Asthma Education and Prevention Program (2007). "Expert Panel 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007". J Allergy Clin Immunol 120.
- Foresi, A, et al. (1993). "Bronchial responsiveness to inhaled propranolol is asthmatic children and adults". Eur Respir J 6 (2): 181–8.
- www.goldcopd.org. Missing or empty
- Burge, PS; Calverley, PM; Jones, PW; Spencer, S; Anderson, JA; Maslen, TK (May 13, 2000). "Randomised, double blind, placebo controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial". BMJ 320 (7245): 1297–303.
- Panning, CA; DeBisschop, M (Feb 2003). "Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease". Pharmacotherapy 23 (2): 183–9. PMID 12587807.
- "Treatment for COPD". NIH.
- Pharmacotherapy of bronchoconstriction in patients with asthma by antiepileptic drugs
- Why Do So Many Winter Olympians Have Asthma?
- Salt Intake, Asthma, and Exercise-Induced Bronchoconstriction: A Review